News and Press Releases
Press releases
Theralase Brain Cancer Pre-Clinical Research Accepted for Publication
Press ReleaseResearch Detailing Advantages of Rutherrin® PhotoDynamic Therapy in deadly brain cancer, GlioBlastoma Multiforme (“GBM”) to be Published in the Journal of Neuro-Oncology Advances Toronto, Ontario – June 25, 2019, Theralase® Techn...
Theralase® Releases 2018 Year End Audited Financial Statements
Press ReleaseToronto, Ontario – April 17, 2019, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated ...
Theralase Releases Amended and Restated 1Q2019 Financial Statements
Press ReleaseToronto, Ontario – June 18, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo D...
Theralase Releases 1Q2019 Financial Statements
Press ReleaseToronto, Ontario – May 30, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase Granted Notice of Acceptance for PhotoDynamic Compounds by Chinese Patent Office
Press ReleaseToronto, Ontario – May 20, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase’s 5th Annual Medical and Scientific Advisory Board Meeting Advances Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Press ReleaseToronto, Ontario – May 13, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Chinese Patent Office Issues Notice of Acceptance for Multiwavelength PhotoDynamic Therapy
Press ReleaseToronto, Ontario – May 7, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo...
Theralase’s Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study Research Presented at the American Urological Association
Press ReleaseToronto, Ontario – May 6, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo...
Theralase Commences Phase II NMIBC Clinical Study
Press ReleaseToronto, Ontario – April 25, 2019, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTCQB), a clinical stage pharmaceutical company dedicated to the research and development of light activated Phot...
Theralase’s Latest Scientific Research to be Presented at the 17th Annual International Photodynamic Association World Congress
Press ReleaseNine Scientific Papers Detailing the Latest Scientific Research of Theralase®’s Anti-Cancer Technology (“ACT”) Platform have been Peer Reviewed and will be Presented at the International Photodynamic Association World Congress Tor...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
